BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36742486)

  • 1. Clinical Outcomes and Prognostic Factors of Locally Advanced Nasopharyngeal Cancer Treated with Intensity Modulated Radiotherapy: First Experience Report from Northeast India.
    Sarma G; Paul M; Nath J; Medhi PP; Bhattacharyya M; Kalita AK
    Indian J Otolaryngol Head Neck Surg; 2022 Dec; 74(Suppl 3):5964-5973. PubMed ID: 36742486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy in locally advanced nasopharyngeal carcinoma: Comparative study at SKIMS Tertiary Care Institute.
    Fatima K; Andleeb A; Sofi MA; Rasool MT; Fir A; Nasreen S; Dar NA
    J Cancer Res Ther; 2022; 18(1):133-139. PubMed ID: 35381774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity Modulated Radiotherapy in Head and Neck Cancer: Initial Experience of the First Treated Cases from North-East India.
    Nath J; Sarma G; Paul M; Bhattacharyya M; Kalita AK; Medhi PP
    Indian J Surg Oncol; 2023 Sep; 14(3):699-706. PubMed ID: 37900646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases.
    Lin S; Lu JJ; Han L; Chen Q; Pan J
    BMC Cancer; 2010 Feb; 10():39. PubMed ID: 20146823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma.
    Ji X; Xie C; Hu D; Fan X; Zhou Y; Zheng Y
    PLoS One; 2013; 8(2):e56208. PubMed ID: 23441169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
    He YX; Wang Y; Cao PF; Shen L; Zhao YJ; Zhang ZJ; Chen DM; Yang TB; Huang XQ; Qin Z; Dai YY; Shen LF
    Chin J Cancer; 2016 Nov; 35(1):96. PubMed ID: 27852284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasopharyngeal carcinoma: Experience and treatment outcome with radical conformal radiotherapy from a tertiary care center in India.
    Kunheri B; Agarwal G; Sunil PS; Nair AR; Pushpaja KU
    Indian J Cancer; 2017; 54(3):502-507. PubMed ID: 29798947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy.
    Ji P; Lu Q; Chen X; Chen Y; Peng X; Chen Z; Lin C; Lin S; Zong J
    Cancer Res Treat; 2023 Oct; 55(4):1113-1122. PubMed ID: 37170497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients.
    Iacovelli NA; Cicchetti A; Cavallo A; Alfieri S; Locati L; Ivaldi E; Ingargiola R; Romanello DA; Bossi P; Cavalieri S; Tenconi C; Meroni S; Calareso G; Guzzo M; Piazza C; Licitra L; Pignoli E; Carlo F; Orlandi E
    Front Oncol; 2020; 10():518110. PubMed ID: 33072562
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study.
    Xu M; Zang J; Luo S; Wang J; Li X
    BMJ Open; 2021 Aug; 11(8):e045417. PubMed ID: 34341036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma.
    Kang M; Wang F; Liao X; Zhou P; Wang R
    Medicine (Baltimore); 2018 Jun; 97(25):e11118. PubMed ID: 29924009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma.
    Wu S; Quan R; Han L; Zhang H; Zhang B; Xu G; Li X
    Medicine (Baltimore); 2020 Jul; 99(30):e21325. PubMed ID: 32791728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human endostatin injection (Endostar) combined with PF chemotherapy and sequential intensity-modulated radiotherapy is tolerable and improves prognosis of locally advanced nasopharyngeal carcinoma: a randomized, open, multicenter phase II clinical study.
    Xu L; Li D; Ji J; Chen Z; Tang X; Chen D; Li X; Bao D; Yan F; Pang Y; Liu S; Zhou Y; Xu X
    Am J Cancer Res; 2022; 12(10):4622-4636. PubMed ID: 36381335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
    Luo Y; Qin Y; Lang J
    Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
    Han L; Lin SJ; Pan JJ; Chen CB; Zhang Y; Zhang XC; Liao XY; Chen QS
    Chin J Cancer; 2010 Feb; 29(2):145-50. PubMed ID: 20109341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.